SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:e2639370-d4b4-422a-98e4-7d7b4804d73a"
 

Search: onr:"swepub:oai:lup.lub.lu.se:e2639370-d4b4-422a-98e4-7d7b4804d73a" > Estimating the harm...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005584naa a2200637 4500
001oai:lup.lub.lu.se:e2639370-d4b4-422a-98e4-7d7b4804d73a
003SwePub
008161111s2016 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/243955
0247 a https://lup.lub.lu.se/record/e2639370-d4b4-422a-98e4-7d7b4804d73a2 URI
0247 a https://doi.org/10.1002/cncr.301922 DOI
0247 a https://gup.ub.gu.se/publication/2439552 URI
040 a (SwePub)lud (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Carlsson, Sigrid V.u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology4 aut0 (Swepub:gu)xcasig
2451 0a Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice : A microsimulation screening analysis
264 c 2016-07-26
264 1b Wiley,c 2016
300 a 8 s.
338 a electronic2 rdacarrier
520 a BACKGROUND: Prostate-specific antigen (PSA) screening and concomitant treatment can be implemented in several ways. The authors investigated how the net benefit of PSA screening varies between common practice versus “good practice.”. METHODS: Microsimulation screening analysis (MISCAN) was used to evaluate the effect on quality-adjusted life-years (QALYs) if 4 recommendations were followed: limited screening in older men, selective biopsy in men with elevated PSA, active surveillance for low-risk tumors, and treatment preferentially delivered at high-volume centers. Outcomes were compared with a base model in which annual screening started at ages 55 to 69 years and were simulated using data from the European Randomized Study of Screening for Prostate Cancer. RESULTS: In terms of QALYs gained compared with no screening, for 1000 screened men who were followed over their lifetime, recommended good practice led to 73 life-years (LYs) and 74 QALYs gained compared with 73 LYs and 56 QALYs for the base model. In contrast, common practice led to 78 LYs gained but only 19 QALYs gained, for a greater than 75% relative reduction in QALYs gained from unadjusted LYs gained. The poor outcomes for common practice were influenced predominantly by the use of aggressive treatment for men with low-risk disease, and PSA testing in older men also strongly reduced potential QALY gains. CONCLUSIONS: Commonly used PSA screening and treatment practices are associated with little net benefit. Following a few straightforward clinical recommendations, particularly greater use of active surveillance for low-risk disease and reducing screening in older men, would lead to an almost 4-fold increase in the net benefit of prostate cancer screening. Cancer 2016;122:3386–3393.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a early detection of cancer/adverse effects
653 a mass screening
653 a prostate-specific antigen/blood
653 a prostatic neoplasms
653 a quality of life
653 a quality-adjusted-life-years
7001 a de Carvalho, Tiago M.u Erasmus University Medical Center4 aut
7001 a Roobol, Monique J.u Erasmus University Medical Center4 aut
7001 a Hugosson, Jonas,d 1955u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology4 aut0 (Swepub:gu)xhugjo
7001 a Auvinen, Anssiu University of Tampere4 aut
7001 a Kwiatkowski, Macieju Städtische Klinikum Braunschweig4 aut
7001 a Villers, Arnauldu University of Lille4 aut
7001 a Zappa, Marcou Cancer Research and Prevention Institute (ISPO)4 aut
7001 a Nelen, Verau Provinciaal Instituut voor Hygiëne4 aut
7001 a Páez, Alvarou Fuenlabrada University Hospital4 aut
7001 a Eastham, James A.u Memorial Sloan-Kettering Cancer Center4 aut
7001 a Lilja, Hansu Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,University of Oxford,Memorial Sloan-Kettering Cancer Center4 aut0 (Swepub:lu)klke-hli
7001 a de Koning, Harry J.u Erasmus University Medical Center4 aut
7001 a Vickers, Andrew J.u Memorial Sloan-Kettering Cancer Center4 aut
7001 a Heijnsdijk, Eveline A Mu Erasmus University Medical Center4 aut
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för urologi4 org
7730 t Cancerd : Wileyg 122:21, s. 3386-3393q 122:21<3386-3393x 0008-543Xx 1097-0142
8564 u https://portal.research.lu.se/files/27487841/16811007.pdfx primaryx freey FULLTEXT
8564 u http://dx.doi.org/10.1002/cncr.30192y FULLTEXT
8564 u https://europepmc.org/articles/pmc5073010?pdf=render
8564 8u https://lup.lub.lu.se/record/e2639370-d4b4-422a-98e4-7d7b4804d73a
8564 8u https://doi.org/10.1002/cncr.30192
8564 8u https://gup.ub.gu.se/publication/243955

Find in a library

  • Cancer (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view